No description available
Author Archives: Globalization and Health
Background: As pharmaceutical firms experience increasing civil society pressure to act responsibly in a changing globalized world, many are expanding and/or reforming their corporate social responsibility (CSR) strategies.
Modern trade negotiations have delivered a plethora of bilateral and regional preferential trade agreements (PTAs), which involve considerable risk to public health, thus placing demands on governments to strengthen administrative regulatory capacities in regard to the negotiation, implementation and on-going management of PTAs.
The Millennium Development Goals (MDGs) galvanized attention, resources and accountability on a small number of health concerns of low- and middle-income countries with unprecedented results.
Background: Development assistance for health (DAH) has grown substantially, totaling more than $31.3 billion in 2013.
Cardiovascular diseases (CVD) are the main cause of morbidity and mortality worldwide.
Background: Focus on “social determinants of health” provides a welcome alternative to the bio-medical illness paradigm.
Background: The current Ebola Virus Disease (EVD) epidemic has ravaged the social fabric of three West African countries and affected people worldwide.
Background: The views of practitioners at the sharp end of health care provision are now recognised as a valuable source of intelligence that can inform efforts to improve patient safety in high-income countries.
Background: The importance of good health is reflected in the fact that more than half of the eight Millennium Development Goals (MDGs) are aimed at improving health status.
Background: An ecological perspective was prominently present in the health promotion movement in the 1980s, but this seems to have faded.
Background: There is a growing recognition of China?s role as a global health donor, in particular in Africa, but there have been few systematic studies of the level, destination, trends, or composition of these development finance flows or a comparison of China?s engagement as a donor with that of more traditional global health donors.
Background: We describe trends in participation by investigators from low- and middle-income countries (LMCs) in publications describing oncology randomized control trials (RCTs) over a decade.
Background: In 2008, the WHO facilitated the primary health care (PHC) revitalisation agenda.